Wongchenko MJ, et al. - An investigation was performed of the connection between tumour programmed death ligand-1 (PD-L1) expression with progression-free survival (PFS) and overall survival (OS), in patients with BRAF mutation–positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. The inference drawn was that the combination cobimetinib and vemurafenib possibly overcame the poor prognosis related to low PD-L1 expression.